These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31629006)

  • 1. Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.
    Davies SS; May-Zhang LS; Boutaud O; Amarnath V; Kirabo A; Harrison DG
    Pharmacol Ther; 2020 Jan; 205():107418. PubMed ID: 31629006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans.
    Rathmacher JA; Fuller JC; Abumrad NN; Flynn CR
    Inflammation; 2023 Aug; 46(4):1343-1352. PubMed ID: 36935449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolevuglandins (isoLGs) as toxic lipid peroxidation byproducts and their pathogenetic role in human diseases.
    Aschner M; Nguyen TT; Sinitskii AI; Santamaría A; Bornhorst J; Ajsuvakova OP; da Rocha JBT; Skalny AV; Tinkov AA
    Free Radic Biol Med; 2021 Jan; 162():266-273. PubMed ID: 33099003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolevuglandins Promote Mitochondrial Dysfunction and Electrophysiologic Abnormalities in Atrial Cardiomyocytes.
    Subati T; Yang Z; Murphy MB; Stark JM; Trykall DZ; Davies SS; Barnett JV; Murray KT
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification by isolevuglandins, highly reactive γ-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function.
    May-Zhang LS; Yermalitsky V; Huang J; Pleasent T; Borja MS; Oda MN; Jerome WG; Yancey PG; Linton MF; Davies SS
    J Biol Chem; 2018 Jun; 293(24):9176-9187. PubMed ID: 29712723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation.
    Mayorov V; Uchakin P; Amarnath V; Panov AV; Bridges CC; Uzhachenko R; Zackert B; Moore CS; Davies S; Dikalova A; Dikalov S
    Redox Biol; 2019 Sep; 26():101300. PubMed ID: 31437812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolevuglandins and cardiovascular disease.
    Davies SS; May-Zhang LS
    Prostaglandins Other Lipid Mediat; 2018 Nov; 139():29-35. PubMed ID: 30296489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr
    Tao H; Huang J; Yancey PG; Yermalitsky V; Blakemore JL; Zhang Y; Ding L; Zagol-Ikapitte I; Ye F; Amarnath V; Boutaud O; Oates JA; Roberts LJ; Davies SS; Linton MF
    Nat Commun; 2020 Aug; 11(1):4084. PubMed ID: 32796843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scavenging Reactive Lipids to Prevent Oxidative Injury.
    May-Zhang LS; Kirabo A; Huang J; Linton MF; Davies SS; Murray KT
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():291-308. PubMed ID: 32997599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scavenging 4-Oxo-2-nonenal.
    Amarnath V; Amarnath K
    Chem Res Toxicol; 2015 Oct; 28(10):1888-90. PubMed ID: 26355561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro.
    Longato L; Andreola F; Davies SS; Roberts JL; Fusai G; Pinzani M; Moore K; Rombouts K
    Free Radic Biol Med; 2017 Jan; 102():162-173. PubMed ID: 27890721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry and analysis of HNE and other prominent carbonyl-containing lipid oxidation compounds.
    Sousa BC; Pitt AR; Spickett CM
    Free Radic Biol Med; 2017 Oct; 111():294-308. PubMed ID: 28192230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prooxidant-initiated lipid peroxidation in isolated rat hepatocytes: detection of 4-hydroxynonenal- and malondialdehyde-protein adducts.
    Hartley DP; Kroll DJ; Petersen DR
    Chem Res Toxicol; 1997 Aug; 10(8):895-905. PubMed ID: 9282839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormetic and regulatory effects of lipid peroxidation mediators in pancreatic beta cells.
    Maulucci G; Daniel B; Cohen O; Avrahami Y; Sasson S
    Mol Aspects Med; 2016 Jun; 49():49-77. PubMed ID: 27012748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U-101033E (2,4-diaminopyrrolopyrimidine), a potent inhibitor of membrane lipid peroxidation as assessed by the production of 4-hydroxynonenal, malondialdehyde, and 4-hydroxynonenal--protein adducts.
    Rohn TT; Nelson LK; Waeg G; Quinn MT
    Biochem Pharmacol; 1998 Nov; 56(10):1371-9. PubMed ID: 9825737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological effect of protein modifications by lipid peroxidation products.
    Gęgotek A; Skrzydlewska E
    Chem Phys Lipids; 2019 Jul; 221():46-52. PubMed ID: 30922835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls.
    Singh M; Kapoor A; Bhatnagar A
    Chem Biol Interact; 2015 Jun; 234():261-73. PubMed ID: 25559856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplified LC/MS assay for the measurement of isolevuglandin protein adducts in plasma and tissue samples.
    Yermalitsky VN; Matafonova E; Tallman K; Li Z; Zackert W; Roberts LJ; Amarnath V; Davies SS
    Anal Biochem; 2019 Feb; 566():89-101. PubMed ID: 30458125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct characterization of protein adducts of the lipid peroxidation product 4-hydroxy-2-nonenal using electrospray mass spectrometry.
    Bruenner BA; Jones AD; German JB
    Chem Res Toxicol; 1995 Jun; 8(4):552-9. PubMed ID: 7548735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolevuglandins as a gauge of lipid peroxidation in human tumors.
    Yan HP; Roberts LJ; Davies SS; Pohlmann P; Parl FF; Estes S; Maeng J; Parker B; Mernaugh R
    Free Radic Biol Med; 2017 May; 106():62-68. PubMed ID: 28189846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.